{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:41:49Z","timestamp":1786466509900,"version":"build-2736575974"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Hosp Pharm"],"abstract":"<jats:p>Background: The role of acetylsalicylic acid (ASA) thromboprophylaxis following elective total hip arthroplasty (THA) remains unclear, given limited high-quality evidence and differing guideline recommendations.\nObjectives: To compare thromboprophylaxis prescribing patterns for ASA and alternative anticoagulants and to determine subsequent health care utilization for patients undergoing elective THA within one Canadian health region.\nMethods: This retrospective cohort study involved adult patients who underwent THA between January and June 2019, comparing those who received ASA with those who received an alternative anticoagulant. Data for drug- and patient-specific characteristics are reported as means and standard deviations for continuous variables and as percentages for categorical variables. Patient characteristics and treatments were compared using \u03c72 and t tests. Multivariable logistic regression was conducted to identify predictors of the choice of treatment (ASA vs rivaroxaban).\nResults: Of the 180 patients who underwent THA in the study period, thromboprophylaxis consisted of ASA for 153 (85.0%) and rivaroxaban for 27 (15.0%). The most common ASA regimen was 325 mg daily (152\/153, 99.3%) for a mean of 43.0 (standard deviation 6.9) days. Significant patient differences between the ASA and rivaroxaban groups included history of malignancy (6.5% vs 51.9%, p &lt; 0.001), previous venous thromboembolism (0% vs 11.1%, p = 0.001), thrombophilia (0% vs 3.7%, p = 0.018), and chemotherapy (0% vs 11.1%, p &lt; 0.001). Patients with a history of malignancy were more likely to receive rivaroxaban than ASA (odds ratio 31.65, 95% confidence interval 18.22 to 2.4 \u00d7 104, p &lt; 0.001). No differences were observed for health care utilization.\nConclusions: ASA was used as thromboprophylaxis after THA for most patients within one Canadian health region. Significant differences in baseline characteristics were noted between patients who received ASA and those who received rivaroxaban.\nKeywords: thromboprophylaxis, acetylsalicylic acid, rivaroxaban, hip replacement\nR\u00c9SUM\u00c9\nContexte : Le r\u00f4le de l\u2019acide ac\u00e9tylsalicylique (AAS) dans la prophylaxie de la thrombose \u00e0 la suite d\u2019une arthroplastie totale de la hanche (ATH) demeure flou, vu la quantit\u00e9 restreinte de donn\u00e9es probantes de haute qualit\u00e9 et les recommandations divergentes des lignes directrices.\nObjectifs : Comparer les sch\u00e9mas de prescription de l\u2019AAS et d\u2019autres anticoagulants pour la prophylaxie de la thrombose; et d\u00e9terminer l\u2019utilisation subs\u00e9quente des soins de sant\u00e9 pour les patients qui subissent une ATH au sein d\u2019une r\u00e9gion sanitaire canadienne.\nM\u00e9thodologie : Cette \u00e9tude de cohorte r\u00e9trospective portait sur des patients adultes ayant subi une ATH entre janvier et juin 2019. Elle comparait ceux ayant re\u00e7u de l\u2019AAS \u00e0 ceux ayant re\u00e7u d\u2019autres anticoagulants. Les donn\u00e9es concernant les caract\u00e9ristiques sp\u00e9cifiques aux patients et aux m\u00e9dicaments sont pr\u00e9sent\u00e9es sous forme de moyennes et d\u2019\u00e9carts-types pour les variables continues, et sous forme de pourcentages pour les variables cat\u00e9gorielles. Les caract\u00e9ristiques et les traitements des patients ont \u00e9t\u00e9 compar\u00e9s \u00e0 l\u2019aide du test du \u03c7\u00b2 et du test t. Une r\u00e9gression logistique multivari\u00e9e a \u00e9t\u00e9 effectu\u00e9e afin de cerner les facteurs pr\u00e9dictifs du choix du traitement (AAS contre rivaroxaban).\nR\u00e9sultats : Parmi les 180 patients ayant subi une ATH au cours de la p\u00e9riode de l\u2019\u00e9tude, la thromboprophylaxie consistait en de l\u2019AAS pour 153 patients (85,0 %) et en du rivaroxaban pour 27 d\u2019entre eux (15,0 %). Le sch\u00e9ma posologique d\u2019AAS le plus courant \u00e9tait de 325 mg par jour (152\/153, 99,3 %) pendant une dur\u00e9e moyenne de 43,0 jours (\u00e9cart-type : 6,9 jours). Des diff\u00e9rences significatives entre les groupes AAS et rivaroxaban ont \u00e9t\u00e9 observ\u00e9es concernant les ant\u00e9c\u00e9dents de malignit\u00e9s (6,5 % contre 51,9 %, p &lt; 0,001), les ant\u00e9c\u00e9dents de thromboembolie veineuse (0 % contre 11,1 %, p = 0,001), la thrombophilie (0 % contre 3,7 %, p = 0,018) et la chimioth\u00e9rapie (0 % contre 11,1 %, p &lt; 0,001). Les patients ayant des ant\u00e9c\u00e9dents de malignit\u00e9s \u00e9taient plus susceptibles de recevoir du rivaroxaban que de l\u2019AAS (rapport de cotes : 31,65; intervalle de confiance \u00e0 95 % : 18,22 \u00e0 2,4 \u00d7 104; p &lt; 0,001). Aucune diff\u00e9rence n\u2019a \u00e9t\u00e9 observ\u00e9e en ce qui concerne le recours aux soins de sant\u00e9.\nConclusions : L\u2019AAS a \u00e9t\u00e9 utilis\u00e9 comme thromboprophylaxie apr\u00e8s une ATH chez la plupart des patients dans une r\u00e9gion sanitaire canadienne. Des diff\u00e9rences significatives dans les caract\u00e9ristiques de base ont \u00e9t\u00e9 observ\u00e9es entre les patients ayant re\u00e7u de l\u2019AAS et ceux ayant re\u00e7u du rivaroxaban.\nMots-cl\u00e9s : thromboprophylaxie, acide ac\u00e9tylsalicylique, rivaroxaban, arthroplastie de la hanche<\/jats:p>","DOI":"10.4212\/cjhp.3599","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:45:59Z","timestamp":1786463159000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Acetylsalicylic Acid with Rivaroxaban or Alternative Anticoagulants for Thromboprophylaxis in Elective Total Hip Arthroplasty: A Retrospective Cohort Study"],"prefix":"10.4212","volume":"78","author":[{"given":"Rebecca","family":"Norman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kielly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwadwo","family":"Bonsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufaro","family":"Chitsike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2732","published-online":{"date-parts":[[2025,7,9]]},"container-title":["Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3599\/5660","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3599\/5661","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3599\/5660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:46:00Z","timestamp":1786463160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/3599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,10]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.3599","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"value":"1920-2903","type":"electronic"},{"value":"0008-4123","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"article-number":"e3599"}}